Central Pharmaceuticals Ltd. (DSE:CENTRALPHL)
Bangladesh
· Delayed Price · Currency is BDT 8.30
+0.10 (1.22%)
At close: Mar 9, 2026
Central Pharmaceuticals Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Revenue | 33.51 | 33.06 | 29.6 | 29.33 | 26 | 148.15 | Upgrade
|
| Revenue Growth (YoY) | -70.02% | 11.68% | 0.93% | 12.81% | -82.45% | 5.75% | Upgrade
|
| Cost of Revenue | 51.13 | 44.19 | 50.21 | 58.36 | 63.58 | 118.89 | Upgrade
|
| Gross Profit | -17.63 | -11.13 | -20.61 | -29.03 | -37.58 | 29.27 | Upgrade
|
| Selling, General & Admin | 12.03 | 11.57 | 16.65 | 18.83 | 15.77 | 22.45 | Upgrade
|
| Other Operating Expenses | - | - | 0.44 | - | - | - | Upgrade
|
| Operating Expenses | 12.03 | 11.57 | 17.09 | 18.83 | 15.77 | 22.45 | Upgrade
|
| Operating Income | -29.65 | -22.7 | -37.7 | -47.86 | -53.35 | 6.82 | Upgrade
|
| Interest Expense | - | - | - | - | -17.36 | -21.36 | Upgrade
|
| Interest & Investment Income | 0.01 | 0.01 | 0.01 | 0 | 0 | 0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.01 | -0.01 | -0.01 | -0.01 | -0.11 | -0.09 | Upgrade
|
| EBT Excluding Unusual Items | -29.65 | -22.7 | -37.71 | -47.87 | -70.82 | -14.63 | Upgrade
|
| Asset Writedown | - | - | -10.59 | - | - | - | Upgrade
|
| Pretax Income | -29.65 | -22.7 | -48.3 | -47.87 | -70.82 | -14.63 | Upgrade
|
| Income Tax Expense | -0.08 | -0.72 | -5.88 | -3.91 | -2.57 | -6.16 | Upgrade
|
| Net Income | -29.57 | -21.98 | -42.42 | -43.96 | -68.25 | -8.47 | Upgrade
|
| Net Income to Common | -29.57 | -21.98 | -42.42 | -43.96 | -68.25 | -8.47 | Upgrade
|
| Shares Outstanding (Basic) | 120 | 120 | 120 | 120 | 120 | 120 | Upgrade
|
| Shares Outstanding (Diluted) | 120 | 120 | 120 | 120 | 120 | 120 | Upgrade
|
| Shares Change (YoY) | -2.27% | - | - | - | - | - | Upgrade
|
| EPS (Basic) | -0.25 | -0.18 | -0.35 | -0.37 | -0.57 | -0.07 | Upgrade
|
| EPS (Diluted) | -0.25 | -0.18 | -0.35 | -0.37 | -0.57 | -0.07 | Upgrade
|
| Free Cash Flow | -0.2 | -0.52 | 2.97 | -0.33 | -1.12 | -4.78 | Upgrade
|
| Free Cash Flow Per Share | -0.00 | -0.00 | 0.03 | -0.00 | -0.01 | -0.04 | Upgrade
|
| Gross Margin | -52.61% | -33.66% | -69.62% | -98.99% | -144.57% | 19.75% | Upgrade
|
| Operating Margin | -88.51% | -68.66% | -127.37% | -163.18% | -205.21% | 4.60% | Upgrade
|
| Profit Margin | -88.27% | -66.49% | -143.31% | -149.88% | -262.51% | -5.72% | Upgrade
|
| Free Cash Flow Margin | -0.59% | -1.57% | 10.02% | -1.11% | -4.31% | -3.22% | Upgrade
|
| EBITDA | -8.32 | -1.08 | -24.25 | -21.11 | -23.59 | 39.71 | Upgrade
|
| EBITDA Margin | -24.83% | -3.28% | -81.92% | -71.98% | -90.75% | 26.80% | Upgrade
|
| D&A For EBITDA | 21.34 | 21.61 | 13.45 | 26.75 | 29.76 | 32.89 | Upgrade
|
| EBIT | -29.65 | -22.7 | -37.7 | -47.86 | -53.35 | 6.82 | Upgrade
|
| EBIT Margin | -88.51% | -68.66% | -127.37% | -163.18% | -205.21% | 4.60% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.